Latest Forum Topics / IPO | Post Reply |
Sihuan Pharmaceutical IPO
|
|
teeth53
Supreme |
19-Mar-2007 17:15
Yells: "don't learn through life, learn to grow with life " |
x 0
x 0 Alert Admin |
Personnal. I go for it, i oredi (applied) to tikam at at ATM. |
Useful To Me Not Useful To Me | |
zhuge_liang
Supreme |
14-Mar-2007 23:38
|
x 0
x 0 Alert Admin |
Sihuan has an enlarged share capital of 470 million shares. Estimated net eps is $0.0478 for FY2006. The IPO will close at 12.00 noon on 21 Mar. Trading is expected to commence on 23 Mar. From the estimated net IPO proceeds of approximately $38.0 million to be raised by the Group,
|
Useful To Me Not Useful To Me | |
|
|
Nostradamus
Supreme |
14-Mar-2007 23:13
|
x 0
x 0 Alert Admin |
Its primary focus is on the R&D, production and sale of cardiocelebral vascular (CV) drugs, which treat diseases affecting the brain, heart and the body's blood vessels. |
Useful To Me Not Useful To Me | |
kennethng
Member |
14-Mar-2007 16:39
|
x 0
x 0 Alert Admin |
Wif the current market.. i doubt this will soar when it starts to trade.. Unlike those previous IPOs when the market is bullish.. Most prob i wont for this.. |
Useful To Me Not Useful To Me | |
firstlady
Member |
14-Mar-2007 14:19
|
x 0
x 0 Alert Admin |
anyone wishes to predict what will be the opening px on its first day of trading...no carrot for the correct prediction...and no stick if you are wrong....goodluck to those who got the ipo. |
Useful To Me Not Useful To Me | |
|
|
Nostradamus
Supreme |
14-Mar-2007 11:06
|
x 0
x 0 Alert Admin |
It's offering 120m shares at $0.43 each. Of this, 5m will be available for public subscription. The IPO price represents an estimated PER of 9x. Profits grew at a compounded anual rate of 71.6% since '03 to reach an estimated RMB89.9m for last year. |
Useful To Me Not Useful To Me | |
zhuge_liang
Supreme |
12-Mar-2007 18:01
|
x 0
x 0 Alert Admin |
The Chinese drug-maker plans to raise around US$40m by selling new shares in an IPO, a source close to the deal said. The company makes drugs used to treat diseases that affect the brain, heart, or blood vessels supplying blood to these organs. The share sale is equivalent to 25.5% of the company, the source said. Daiwa Securities SMBC Singapore is the lead manager. The company plans to use the proceeds for R&D, and to increase production. It also plans to expand its business in foreign markets such as the United States, Japan, Korea and Europe. |
Useful To Me Not Useful To Me |